HomeAI · summaries
Storia in 4 fonti
Agios’ second shot at sickle cell disease falls short
Agios' PK activator tebapivat looked no better than the first-generation agents in sickle cell disease, although it's awaiting approval for mitapivat in the same condition.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Agios scraps sickle cell drug
The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.
- ·
investors.com
Why This Novo Rival Just Pulled A Bearish Move
Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.
